NPPA Revises Prices for 543 Cancer Drug Brands, Generics Cut but Patented Drugs Unchanged
The National Pharmaceutical Pricing Authority (NPPA) has revised maximum retail prices for 543 anti-cancer drug brands, effective November 9, following a cap on trade margins for 137 non-scheduled medicines. Price cuts exceed 90% for many generics and biosimilars, offering potential relief to patients. However, prices of several high-cost patented drugs remain unchanged, raising concerns among experts and activists about affordability and the effectiveness of the reforms. The Supreme Court is reviewing the issue amid calls for broader, cost-based price controls and improved access to cancer treatment.
First-hand measurement across 15 sources
We measured how 15 outlets covered this story. Coverage leans balanced overall (Left 29%, Centre 71%, Right 0%). Overall sentiment is neutral (57/100). Lens Score 42/100.
Outlets measured: deccanherald, mint, indianexpress, theprint, northeastnow, theassamtribune, ndtv, theprint, and 7 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 1 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment ranged widely across outlets — from 32/100 to 75/100 — a sign the coverage itself was contested, not just reported.
Coverage timeline
firstpost broke this story on 28 Oct, 03:35 pm. Other outlets followed.